ClinicalTrials.gg
RecruitingNCT06762964Updated May 6, 2026

CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

A Phase 2 interventional study of Dapagliflozin tablet and Placebo Tablet in Fontan Circulation, Single Ventricle Heart Disease and HFpEF - Heart Failure With Preserved Ejection Fraction, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.

Planned enrollment
55th of 59
27 · median 100
Started
2025
with 4 others
Phase 2
9 of 59
4 open now
Primary completion
2027-02
later than 10 of 18 live
Registered
50th of 59
by date
Lead sponsor
2 of 59
Mayo Clinic

Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 55th largest by planned enrollment, is one of 5 that started in 2025, is one of 9 in phase 2, reaches primary completion later than 10 of the 18 other live ones, and was the 50th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing dapagliflozin in Heart Failure, or all of them as a file.
02

Study summary

The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 3 months affects peripheral venous pressure at rest and during exercise in adults with failing Fontan circulation.

03

Conditions studied

  • Fontan Circulation
  • Single Ventricle Heart Disease
  • HFpEF - Heart Failure With Preserved Ejection Fraction

Browse trials for

Keywords

  • Fontan
  • HFpEF
  • SGLT2 inhibitors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed prior to any study specific procedures
  2. History of Fontan procedure
  3. Male or female subject
  4. Age ≥ 18
  5. Symptoms of dyspnea ( II-IV) with no non-cardiac or ischemia explanation
  6. Elevated peripheral venous pressure (PVP) at rest or during exercise (≥20 mmHg) ascertained at Visit 1. Patients that have consented to study procedures but do not meet this invasive criterion will be considered as screen failures and will not be randomized.

Exclusion criteria

Exclusion Criteria

  1. Type I diabetes
  2. Any of the following medications: Insulin or Pramlintide, Sandostatin, Akeega (abiraterone acetate), Growth Hormone (Somatogrogon-GHLA), Lithium, Chloroquine, Hydroxychloroquine, Thioctic acid (alpha lipoic acid), Empagliflozin or Canagliflozin
  3. Recent hospitalization (\<30 days) or revascularization (\<90 days)
  4. Significant valvular heart disease (≥moderate stenosis, >moderate regurgitation)
  5. Significant Fontan obstruction with resting SVC-IVC gradient >4 mmHg
  6. Primary cardiomyopathy (such as amyloid)
  7. Dyspnea due to primary lung disease or myocardial ischemia in the opinion of the investigator
  8. Severe anemia ( \<9 gm/dl)
  9. Severe kidney disease (estimated \<30) or liver disease
  10. Women of not willing to use a medically accepted method of OR who are currently pregnant (confirmed with positive pregnancy test) or breast feeding.
  11. History of serious reaction to dapagliflozin
  12. Subjects on dialysis
  13. Subjects with severe liver disease with history of decompensation including ascites or encephalopathy or variceal bleeding
  14. Single ventricle heart disease without Fontan palliation
  15. Those with a history of Fontan takedown
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Dapagliflozin

    Drug: Dapagliflozin tablet

  • Placebo comparator
    Placebo

    Drug: Placebo Tablet

Interventions

  • DrugDapagliflozinStudies of DapagliflozinDapagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patient will take a 10mg tablet of Dapagliflozin once daily for 12 weeks

  • DrugPlacebo Tablet

    Patient will take 10mg placebo tablet once daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Peripheral venous pressure (PVP) at rest

    Peripheral venous pressure (PVP) at rest will be determined by Stress Echocardiogram. Peripheral venous pressure (PVP) is measured in millimeters of mercury (mmHg).

    Time frame: Baseline, 12 Weeks

  2. Peripheral venous pressure (PVP) with feet elevated

    Peripheral venous pressure (PVP) with feet elevated will be determined by Stress Echocardiogram. Peripheral venous pressure (PVP) is measured in millimeters of mercury (mmHg).

    Time frame: Baseline, 12 Weeks

  3. Peripheral venous pressure (PVP) at 20W exercise

    Peripheral venous pressure (PVP) at 20W exercise will be determined by Stress Echocardiogram. Peripheral venous pressure (PVP) is measured in millimeters of mercury (mmHg).

    Time frame: Baseline, 12 Weeks

Secondary outcomes

  1. Cardiac output at rest

    Cardiac output measures the amount of blood the heart pumps per minute. It is calculated by Cardiac Output= Oxygen Consumption/(Arterial - Venous Oxygen Content Difference). Cardiac output will be measured in liters per minute (L/min).

    Time frame: Baseline, 12 Weeks

  2. Cardiac output with exercise

    Cardiac output measures the amount of blood the heart pumps per minute. It is calculated by Cardiac Output= Oxygen Consumption/(Arterial - Venous Oxygen Content Difference). Cardiac output will be measured in liters per minute (L/min).

    Time frame: Baseline, 12 Weeks

  3. Peak oxygen consumption (VO2) during exercise

    Peak oxygen consumption (VO2) is measured in milliliters of oxygen per minute (mL/min).

    Time frame: Baseline, 12 Weeks

  4. Change in plasma volume

    Plasma volume will be determined by radiolabeled iodinated albumin (131I, 5-25 μCu) indicator dilution technique (BVA-100 Blood Volume Analyzer, Daxor Corp, NY). Plasma volume will be measured in milliliters (mL).

    Time frame: Baseline, 12 Weeks

  5. Change in blood volume

    Blood volume will be determined by radiolabeled iodinated albumin (131I, 5-25 μCu) indicator dilution technique (BVA-100 Blood Volume Analyzer, Daxor Corp, NY). Blood volume will be measured in milliliters (mL).

    Time frame: Baseline, 12 Weeks

  6. SF-36 quality of life (QOL)

    SF-36 quality of life (QOL) questionnaire is a 36-question questionnaire that evaluates a patient's quality of life. The score range is from 0-100, with a higher score reflecting a better quality of life.

    Time frame: Baseline, 12 Weeks

  7. Change in fat mass

    Fat mass will be determined by Dual Energy X-ray Absorptiometry Scan. Fat mass will be measured in kilograms (kg).

    Time frame: Baseline, 12 Weeks

  8. Change in fat free mass

    Fat free mass will be determined by Dual Energy X-ray Absorptiometry Scan. Fat free mass will be measured in kilograms (kg).

    Time frame: Baseline, 12 Weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Feb 2027, 21 months after the start.

Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 21 months is below that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 8, 2025
StartActual
May 16, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06762964
Lead sponsor
Mayo Clinic
Responsible party
Luke J. Burchill (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Jan 8, 2025
Start date
May 16, 2025
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
May 6, 2026

Study contacts

Amanda Wozniak
Contact
Wozniak.Amanda@mayo.edu
507-266-1976
Yusef Maarouf
Contact
Maarouf.Yusef@mayo.edu
507-422-5755
Luke Burchill, M.B.B.S., Ph.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion